肿瘤电场治疗高级别胶质瘤的系统综述
该研究按PRISMA指南系统检索截至2019年2月的文献,最终纳入9项研究、共1191例接受肿瘤电场治疗(TTF)的高级别胶质瘤患者。随机临床试验显示TTF改善新诊断胶质母细胞瘤患者生存,但未改善复发患者生存;皮肤不良反应是主要不良事件。综述指出研究设计、生活质量和治疗费用方面仍存疑虑。
要点
- TTF改善新诊断胶质母细胞瘤患者生存,但未改善复发患者生存。
- 皮肤不良反应是TTF相关的主要不良事件。
- 研究设计、生活质量和治疗费用仍是TTF的主要争议点。
核心结论
- TTF已在多项研究中评估安全性和有效性,但研究设计、生活质量和治疗费用方面仍存疑虑。
研究设计与样本
- 按PRISMA指南系统检索数据库建库至2019年2月的文献,最终纳入9项研究。
- 纳入研究包括2项试点临床试验、2项随机临床试验和5项回顾性研究。
- 共识别1191例接受TTF的高级别胶质瘤患者。
主要发现
- 随机临床试验中,TTF改善新诊断胶质母细胞瘤患者生存,但未改善复发胶质母细胞瘤患者生存。
- 皮肤不良反应是与TTF相关的主要不良事件。
临床怎么用
- 对于新诊断胶质母细胞瘤,TTF可作为改善生存的治疗选择之一。
- 使用TTF时需关注皮肤不良反应的监测与管理。
- 复发胶质母细胞瘤患者从TTF中生存获益未获随机临床试验证实。
局限性
- 研究设计、生活质量和治疗费用方面存在疑虑。
- 需进一步研究TTF的疗效及联合方案中的相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tumor treating fields (TTF) is a unique treatment modality that utilizes alternating electric fields to deliver therapy. Treatment effects have been assessed in patients with newly diagnosed and recurrent glioblastoma in clinical trials and retrospective studies. While the results of these studies led to FDA approval for both populations, a portion of the neuro-oncology and neurosurgery community remains skeptical of TTF. Thus, this review aims to systematically summarize and evaluate prior studies investigating the efficacy and safety of TTF in patients with high-grade gliomas. METHODS: A systematic review of the literature was performed according to PRISMA guidelines from database inception through February 2019. To be included, studies must have investigated the efficacy of TTF in adult high-grade glioma patients. RESULTS: In total, 852 studies were initially identified, 9 of which met final inclusion criteria. In total, 1191 patients were identified who received TTF. Included studies consisted of two pilot clinical trials, two randomized clinical trials, and five retrospective studies. In randomized clinical trials, TTF improved survival for newly diagnosed glioblastoma patients but not for recurrent glioblastoma patients. Adverse skin reactions were the primary adverse effect associated with TTF. CONCLUSION: While TTF has been evaluated for safety and efficacy in a number of studies, concerns remain regarding study design, quality of life, and cost of therapy. Further investigation is needed regarding the therapy, and ongoing trials are already underway to provide more data regarding therapy outcomes and interactions in combination regimens.
引用
- Shah PP, White T, Khalafallah AM, et al. A systematic review of tumor treating fields therapy for high-grade gliomas. J Neurooncol. 2020. PMID: 32578135. doi:10.1007/s11060-020-03563-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。